Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are medications that help to relax the muscles in the airways, making it easier to breathe. In Norway, the market for bronchodilator drugs has been experiencing certain trends and developments.
Customer preferences: The preferences of customers in Norway for bronchodilator drugs are largely influenced by their healthcare system. The country has a universal healthcare system that is funded by taxes, which means that most of the cost of healthcare is covered by the government. This has led to a focus on cost-effectiveness in the healthcare system, with an emphasis on the use of generic medications.
Trends in the market: One of the major trends in the bronchodilator drugs market in Norway is the increasing use of inhalers. Inhalers are preferred over other forms of bronchodilator drugs because they are more targeted and have fewer side effects. Another trend is the increasing use of combination medications, which contain two or more bronchodilator drugs in a single inhaler. This is seen as a more convenient and cost-effective option for patients.
Local special circumstances: Norway has a high prevalence of asthma and other respiratory diseases, which has led to a high demand for bronchodilator drugs. Additionally, the country has a cold climate, which can exacerbate respiratory symptoms and increase the need for these medications.
Underlying macroeconomic factors: The Norwegian healthcare system is heavily regulated, with the government playing a large role in the pricing and reimbursement of medications. This has led to a focus on cost-effectiveness in the healthcare system, with a preference for generic medications and a push for more efficient use of resources. Additionally, the country has a high standard of living and a strong economy, which has allowed for investment in healthcare infrastructure and research.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
